| Biomarker ID | 1332 |
| PMID | 24512523 |
| Year | 2014 |
| Biomarker | UAP1+ PDLIM5+ IMPDH2+ HSPD1+ PCA3+ TMPRSS2+ ERG+ GAPDH+ B2M+age+sPSA level |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Urine + Plasma |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Gleason Score <7 Vs Gleason Score ≥ 7 |
| Type of Biomarker | Prognostic |
| Cohort | Training set included 70 patients (35 with biopsy-confirmed PCa and 35 with BPH), and the testing set included 51 patients (26 with biopsy- confirmed PCa and 25 with BPH) . GS ≥ 7 (aggressive PCa; n = 32) from the others (GS < 7 and BPH; n=89). |
| Senstivity | 99% |
| Specificity | 47% |
| AUC | Training = 0.87; Testing = 0.88 |
| Accuracy | NA |
| Level Of Significance | NA |
| Method Used | RT-PCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |